Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:42:56.621Z.
Calculation as of: 2026-10-06T19:42:56.621Z.
Quote observation: 2026-10-06T19:40:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 310997c20848bd5012eb98bb82f11fa46ca59880ef1b58a452bebfeaa3e5ded1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$538.80M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$539.25M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$527.99M
Price/FCF Ratio
30.16
TTM Avg
34.94
3Y Avg
46.00
5Y Avg
46.00
Market Cap
$554.05M
Price/FCF Ratio
N/A
TTM Avg
67.09
3Y Avg
65.49
5Y Avg
24.64
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $538.80M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $539.25M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $535.91M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $529.60M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.25M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $527.99M | 30.16 | 34.94 | 46.00 | 46.00 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $525.16M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $554.05M | N/A | 67.09 | 65.49 | 24.64 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.33M | N/A | 0.26 | 0.26 | 0.26 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
